Brief: Neumora Therapeutics Announces Initiation Of Phase 1 Clinical Study Of M4 Positive Allosteric Modulator NMRA-898
27/10/2025 11:02
Oct 27 (Reuters) - Neumora Therapeutics Inc NMRA.O: NEUMORA THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF M4 POSITIVE ALLOSTERIC MODULATOR NMRA-898 NEUMORA THERAPEUTICS INC - PLANS M4 FRANCHISE UPDATE BY MID-2026 Source text: ID:nGNX6TZXwl Further company coverage: NMRA.O
Recent news on Neumora Therapeutics
See all newsNeumora Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex